source
- Disc Medicine's rare sun-sensitivity drug meets all endpoints in Phase 3 trialDisc Medicine announced that its experimental therapy for a rare condition that makes sun exposure painful has completed a Phase 3 study. The trial reported success on every primary and secondary…
- Eli Lilly teams with Hong Kong's Metis TechBio in up to $1.1 billion AI nanoparticle partnershipEli Lilly has entered a partnership with Hong Kong‑based Metis TechBio to access an artificial‑intelligence driven platform for designing lipid nanoparticles that can improve drug delivery. The co…